U.S. Markets close in 5 hrs 11 mins

BIND Therapeutics, Roche collaborate on discovery of novel nanomedicines

BIND Therapeutics (BIND) announced that it has entered into a research agreement with Roche (RHHBY) to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands.